戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (left1)

通し番号をクリックするとPubMedの該当ページを表示します
1                                              Castleman disease (CD) describes a group of at least 4 d
2                                              Castleman disease (CD) in the context of human immunodef
3                                              Castleman disease (CD) is a lymphoproliferative disorder
4                                              Castleman disease (CD) is a rare hematologic disorder ch
5                                              Castleman disease (CD), a heterogeneous group of disorde
6                                              Castleman disease can occur in association with autoimmu
7                                              Castleman disease was initially described over 50 years
8                                              Castleman disease, an unusual condition of unknown cause
9                                              Castleman's Awareness & Research Effort/Castleman Diseas
10                                              Castleman's disease is a rare primary disease of the lym
11 irus (HIV)-associated lymphadenopathy with a Castleman's disease-like appearance.
12 thritis, hypercalcemia, cancer cachexia, and Castleman's disease.
13 ondylitis, familial Mediterranean fever, and Castleman's disease.
14  less commonly primary effusion lymphoma and Castleman's disease; these neoplastic diseases are repor
15 posi sarcoma, primary effusion lymphoma, and Castleman disease.
16 osi sarcoma, body cavity-based lymphoma, and Castleman disease.
17 si's sarcoma, primary effusion lymphoma, and Castleman's disease are the major malignancies associate
18 si's sarcoma, primary effusion lymphoma, and Castleman's disease, encodes several pathogenically impo
19 i's sarcoma, body cavity-based lymphoma, and Castleman's disease.
20 si's sarcoma, primary effusion lymphoma, and Castleman's disease.
21 teritis, as well as other conditions such as Castleman disease and cytokine release syndrome.
22  the original description of UCD by Benjamin Castleman in 1954.
23 herapies successful in the treatment of both Castleman disease and associated autoimmune disease.
24 oborate the experimental results obtained by Castleman and co-workers.
25  or HIV infection or diseases known to cause Castleman-like histopathology were excluded.
26 ganomegaly, potentially including coexisting Castleman disease, endocrinopathy, monoclonal plasma cel
27 tic pemphigus (including 10 with concomitant Castleman's disease) nor from 19 patients with pemphigus
28  Inclusion criteria were pathology-confirmed Castleman's disease in multiple nodes and minimum clinic
29 nd at least 1 of the other 3 major criteria (Castleman disease, sclerotic bone lesions, or elevated V
30 e as an imaging modality for differentiating Castleman's disease from lymphoma.
31 of the atypical lymphoproliferative disorder Castleman's disease (CD).
32                                 Disseminated Castleman disease manifests with diffuse mediastinal lym
33                   Patients with disseminated Castleman disease (n = 6) typically had the plasma cell
34      Castleman's Awareness & Research Effort/Castleman Disease Collaborative Network, Penn Center for
35 ng of pathogenic cell types and cytokines in Castleman disease have allowed the development of target
36 from January, 1995, with keywords including "Castleman's disease" and "giant lymph node hyperplasia".
37 ) are associated with Kaposi's sarcoma (KS), Castleman's disease, and body cavity-based lymphomas (BC
38 V-8) and its etiologic associations with KS, Castleman's disease, and primary effusion lymphomas.
39 ional criteria were included: a bone lesion, Castleman disease, organomegaly (or lymphadenopathy), en
40                                    Localized Castleman disease manifests as either a solitary, well-c
41                      Patients with localized Castleman disease (n = 24) typically had the hyaline-vas
42                                 Multicentric Castleman disease (MCD) is a lymphoproliferative disorde
43                                 Multicentric Castleman disease and hemophagocytic syndrome are other
44                                 Multicentric Castleman's disease (MCD) describes a heterogeneous grou
45                                 Multicentric Castleman's disease describes a group of poorly understo
46                                 Multicentric Castleman's disease is a rare lymphoproliferative disord
47 I 0.26-1.52): 3 skin-only KS, 1 multicentric Castleman disease, 1 allograft KS.
48 et of cells in lytically active multicentric Castleman disease lesions.
49               Finally, although multicentric Castleman disease is not a neoplastic condition, it is a
50  primary effusion lymphoma, and multicentric Castleman desease.
51 ry effusion lymphoma (PEL), and multicentric Castleman disease (MCD) patients.
52 gent of Kaposi sarcoma (KS) and multicentric Castleman disease (MCD), a life-threatening, virally ind
53 ary effusion lymphoma (PEL) and multicentric Castleman disease (MCD).
54 ry effusion lymphoma (PEL), and multicentric Castleman disease (MCD).
55 ary effusion lymphoma (PEL) and multicentric Castleman disease (MCD).
56 ry effusion lymphoma (PEL), and multicentric Castleman disease (MCD).
57                   Localized and multicentric Castleman disease are different clinical disorders with
58 s primary effusion lymphoma and multicentric Castleman disease in AIDS patients.
59 ry effusion lymphoma (PEL), and multicentric Castleman disease, encodes four interferon regulatory fa
60  primary effusion lymphoma, and multicentric Castleman disease.
61 ary effusion lymphoma (PEL) and multicentric Castleman disease.
62  TbetaRII in Kaposi sarcoma and multicentric Castleman disease.
63 ry effusion lymphoma (PEL), and multicentric Castleman disease.
64 ry effusion lymphoma (PEL), and multicentric Castleman disease.
65 s primary effusion lymphoma and multicentric Castleman disease.
66 phoma (PEL) cell lines, PEL and multicentric Castleman's disease (MCD) tumors, Kaposi's sarcoma lesio
67 ry effusion lymphoma (PEL), and multicentric Castleman's disease (MCD), all of which are viewed as cy
68 ry effusion lymphoma (PEL), and multicentric Castleman's disease (MCD), in addition to an MCD-related
69 iated Kaposi's sarcoma, PEL and multicentric Castleman's disease (MCD), in addition to proinflammator
70 ry effusion lymphoma (PEL), and multicentric Castleman's disease (MCD), three diseases that frequentl
71 ry effusion lymphomas (PEL) and multicentric Castleman's disease (MCD).
72 primary effusion lymphomas, and multicentric Castleman's disease (MCD).
73 ry effusion lymphoma (PEL), and multicentric Castleman's disease (MCD).
74 ry effusion lymphoma (PEL), and multicentric Castleman's disease (MCD).
75 ry effusion lymphoma (PEL), and multicentric Castleman's disease (MCD).
76 ry effusion lymphoma (PEL), and multicentric Castleman's disease (MCD).
77 ary effusion lymphoma (PEL) and multicentric Castleman's disease (MCD).
78  primary effusion lymphoma, and multicentric Castleman's disease (MCD).
79 ry effusion lymphoma (PEL), and multicentric Castleman's disease (MCD).
80 ry effusion lymphoma (PEL), and multicentric Castleman's disease through autocrine or paracrine mecha
81 lopment of Kaposi's sarcoma and multicentric Castleman's disease, as well as a rare form of B cell ly
82 h primary effusion lymphoma and multicentric Castleman's disease, as well as its namesake Kaposi's sa
83 g primary effusion lymphoma and multicentric Castleman's disease.
84 ary effusion lymphoma (PEL) and multicentric Castleman's disease.
85  primary effusion lymphoma, and multicentric Castleman's disease.
86 ry effusion lymphoma (PEL), and multicentric Castleman's disease.
87 f primary effusion lymphoma and multicentric Castleman's disease.
88 g primary effusion lymphoma and multicentric Castleman's disease.
89 primary effusion lymphomas, and multicentric Castleman's disease.
90  primary effusion lymphoma, and multicentric Castleman's disease.
91  primary effusion lymphoma, and multicentric Castleman's disease.
92  primary effusion lymphoma, and multicentric Castleman's disease.
93  primary effusion lymphoma, and multicentric Castleman's disease.
94 ry effusion lymphoma (PEL), and multicentric Castleman's disease.
95  primary effusion lymphoma, and multicentric Castleman's disease.
96  primary effusion lymphoma, and multicentric Castleman's disease.
97 f primary effusion lymphoma and multicentric Castleman's disease.
98  primary effusion lymphoma, and multicentric Castleman's disease.
99  primary effusion lymphoma, and multicentric Castleman's disease.
100 n primary effusion lymphoma and multicentric Castleman's disease.
101 , primary effusion lymphoma and multicentric Castleman's disease.
102  primary effusion lymphoma, and multicentric Castleman's disease.
103  primary effusion lymphoma, and multicentric Castleman's disease.
104 ry effusion lymphoma (PEL), and multicentric Castleman's disease.
105  primary effusion lymphoma, and multicentric Castleman's disease.
106  primary effusion lymphoma, and multicentric Castleman's disease.
107  primary effusion lymphoma, and multicentric Castleman's disease.
108  primary effusion lymphoma, and multicentric Castleman's disease.
109 y effusion B-cell lymphoma, and multicentric Castleman's disease.
110  primary effusion lymphoma, and multicentric Castleman's disease.
111 associated Kaposi's sarcoma and multicentric Castleman's disease.
112 ry effusion lymphoma (PEL), and multicentric Castleman's disease.
113 ry effusion lymphoma (PEL), and multicentric Castleman's disease.
114 ry effusion lymphoma (PEL), and multicentric Castleman's disease.
115  primary effusion lymphoma, and multicentric Castleman's disease.
116  primary effusion lymphoma, and multicentric Castleman's disease; in all of these diseases, interleuk
117 ated with both malignancies and multicentric Castleman's disease; the latter is a rare angiolymphopro
118                  HIV-associated multicentric Castleman disease (HIV MCD) is a rare lymphoproliferativ
119 ful treatment of HIV-associated multicentric Castleman disease (HIV+MCD) with rituximab-based approac
120                  HIV-associated multicentric Castleman disease (HIV-MCD) is a rare lymphoproliferativ
121                  HIV-associated multicentric Castleman disease (HIV-MCD) presents with systemic sympt
122 oma (KS) herpesvirus-associated multicentric Castleman disease (KSHV-MCD) is a lymphoproliferative di
123 a herpesvirus (KSHV)-associated multicentric Castleman disease (KSHV-MCD) is characterized by severe
124  recognition of KSHV-associated multicentric Castleman disease (MCD) as a distinct lymphoproliferativ
125 a herpesvirus (KSHV)-associated multicentric Castleman disease (MCD) is a lymphoproliferative disorde
126 a herpesvirus (KSHV)-associated multicentric Castleman disease (MCD) is a lymphoproliferative inflamm
127 a herpesvirus (KSHV)-associated multicentric Castleman disease (MCD) is a polyclonal B-cell lymphopro
128                  HIV-associated multicentric Castleman disease (MCD) is associated with a high risk o
129 lymphoma (PEL), KSHV-associated multicentric Castleman disease (MCD), and KS inflammatory cytokine sy
130 itary (EC) PEL, KSHV-associated multicentric Castleman disease (MCD), KSHV+ diffuse large B-cell lymp
131  diagnosed with KSHV-associated multicentric Castleman disease at autopsy.
132 d herpesvirus (KSHV)-associated multicentric Castleman disease has increased.
133 aposi sarcoma, HHV-8-associated multicentric Castleman disease with microlymphomas and a severe hemop
134 on lymphoma and KSHV-associated multicentric Castleman disease, which are B-cell lymphoproliferative
135 between PEL and KSHV-associated multicentric Castleman disease.
136  (IL)-6 related KSHV-associated multicentric Castleman disease.
137 man herpesvirus 8 (HHV8) causes multicentric Castleman's disease in immunosuppressed patients.
138  lymphoproliferative disorders, multicentric Castleman's disease and primary effusion lymphoma.
139 ted in KSHV-positive cells from multicentric Castleman's disease (MCD) and Kaposi's sarcoma (KS) lesi
140                      Idiopathic multicentric Castleman disease (iMCD) is a hematologic illness involv
141                      Idiopathic multicentric Castleman disease (iMCD) is a rare and poorly understood
142                      Idiopathic multicentric Castleman disease (iMCD) is a rare and poorly-understood
143                      Idiopathic multicentric Castleman disease (iMCD) is a rare cytokine-driven disor
144                      Idiopathic multicentric Castleman disease (iMCD) is a rare hematologic illness o
145  clinical subtype of idiopathic multicentric Castleman disease (iMCD), consists of a constellation of
146 t-line treatment for idiopathic multicentric Castleman disease on the basis of durable efficacy and s
147 red by patients with idiopathic multicentric Castleman disease.
148 of 128 patients with idiopathic multicentric Castleman's disease had a diagnosis of a separate malign
149 -line treatments for idiopathic multicentric Castleman's disease included corticosteroids (47/128 [37
150 Clinical features of idiopathic multicentric Castleman's disease included multicentric lymphadenopath
151    128 patients with idiopathic multicentric Castleman's disease met all inclusion criteria for the s
152 ed information about idiopathic multicentric Castleman's disease represents a major challenge for cli
153 or 127 patients with idiopathic multicentric Castleman's disease were presented from clinical trials,
154 ent, and outcomes of idiopathic multicentric Castleman's disease, which accounts for at least 33% of
155 for, and outcomes of idiopathic multicentric Castleman's disease.
156 uch cases are called idiopathic multicentric Castleman's disease.
157 pic (IgMlambda) plasmablasts in multicentric Castleman disease (MCD).
158  (UCD) or the dominant focus in multicentric Castleman's disease (MCD), nature of the surgical approa
159 ted with human herpesvirus-8 in multicentric Castleman's disease support lytic replication, so that c
160      K1 was readily detected in multicentric Castleman's disease tissues, whereas it was not detected
161 odgkin's lymphomas (NHL) and in multicentric Castleman's disease.
162 y-based lymphomas (BCBL) and in multicentric Castleman's disease.
163 V-associated diseases including multicentric Castleman's disease and non-Hodgkin's lymphoma.
164 ncluding Kaposi's sarcoma (KS), multicentric Castleman's disease (MCD), and primary effusion lymphoma
165 inked to Kaposi's sarcoma (KS), multicentric Castleman's disease (MCD), and primary effusion lymphoma
166 found in Kaposi's sarcoma (KS), multicentric Castleman's disease, and primary effusion lymphomas.
167 vestigated in patients with KS, multicentric Castleman disease (MCD), and primary effusion lymphoma.
168 rus (HIV)-infected men with KS, multicentric Castleman disease, or primary effusion lymphoma and 8 HI
169 ute to the pathogenesis of KSHV multicentric Castleman disease (MCD).
170 oma, primary effusion lymphoma, multicentric Castleman's disease, and KSHV inflammatory cytokine synd
171 ses primary effusion lymphomas, multicentric Castleman's disease, and Kaposi's sarcoma.
172 nt of three human malignancies: multicentric Castleman's disease, primary effusion lymphoma, and Kapo
173 3%) patients with HHV8-negative multicentric Castleman's disease from 1923 cases of multicentric Cast
174      The cause of HHV8-negative multicentric Castleman's disease is idiopathic; such cases are called
175 plasia to monoclonal neoplasia: multicentric Castleman's disease (CD), Kaposi's sarcoma (KS), and pri
176 reported as a heralding sign of multicentric Castleman disease (MCD) and other lymphoproliferative di
177 been described in some cases of multicentric Castleman disease (MCD).
178 lymphoma (PEL), and a subset of multicentric Castleman disease (MCD).
179 on lymphoma (PEL) and a form of multicentric Castleman's disease (MCD) are both caused by Kaposi sarc
180 ymphomas (PEL), and a subset of multicentric Castleman's disease (MCD).
181 homas (BCBLs) and in lesions of multicentric Castleman's disease (MCD).
182 s, the plasmablastic variant of multicentric Castleman's disease and PEL.
183 (KS), the plasmablastic form of multicentric Castleman's disease, and primary effusion lymphoma.
184 (KS), the plasmablastic form of multicentric Castleman's disease, and primary effusion lymphoma.
185 ion lymphoma, and some forms of multicentric Castleman's disease.
186 a and the plasmablastic form of multicentric Castleman's disease.
187 n lymphoma and in some cases of multicentric Castleman's disease.
188 sion lymphoma and some cases of multicentric Castleman's disease.
189 , and from a high proportion of multicentric Castleman's disease.
190 nd the plasmablastic variant of multicentric Castleman's disease.
191 or at least 33% of all cases of multicentric Castleman's disease.
192 an's disease from 1923 cases of multicentric Castleman's disease.
193  effusion lymphoma (PEL) and/or multicentric Castleman disease (MCD), and in 18 (60.0%) of 30 HIV(+),
194 er primary effusion lymphoma or multicentric Castleman disease B-cell malignancies, and from polyclon
195 entation as having localized or multicentric Castleman disease.
196 rimary effusion lymphoma (PEL), multicentric Castleman disease (MCD), and MCD-associated plasmablasti
197 rimary effusion lymphoma (PEL), multicentric Castleman's disease (MCD), and the inflammation-driven n
198 rimary effusion lymphoma (PEL), multicentric Castleman's disease, and two inflammatory diseases.
199 tuximab in posttrans-plantation multicentric Castleman disease patients and non-neoplastic HHV8-assoc
200    HIV-associated plasmablastic multicentric Castleman disease is an increasingly frequent diagnosis.
201 ion lymphoma, and plasmablastic multicentric Castleman's disease.
202 sed lymphomas, and AIDS-related multicentric Castleman's disease.
203 tent lymphadenopathy resembling multicentric Castleman disease in rhesus macaques (RMs) coinfected wi
204 ogic agent of Kaposi's sarcoma, multicentric Castleman's disease, and AIDS-associated primary effusio
205 tive agent of Kaposi's sarcoma, multicentric Castleman's disease, and primary effusion lymphoma.
206 e for patients with symptomatic multicentric Castleman's disease and well tolerated with prolonged ex
207 ative patients with symptomatic multicentric Castleman's disease.
208 ive agent of two B cell tumors, multicentric Castleman disease (MCD) and primary effusion lymphoma (P
209  etiologic agent for KS tumors, multicentric Castleman's disease, and primary effusion lymphomas.
210  lymphoma, and plasma cell-type multicentric Castleman disease (MCD).
211 erpesvirus 8 is associated with multicentric Castleman disease (MCD) and primary effusion lymphoma (P
212 tral/South America), and 2 with multicentric Castleman disease (MCD).
213 ase (2 with visceral KS, 1 with multicentric Castleman disease, and 1 with primary effusion lymphoma)
214 6-in HIV-negative patients with multicentric Castleman's disease.
215 etermine the cellular and molecular basis of Castleman Disease (CD), we analyze the spatial proteome
216 ces in understanding the biological basis of Castleman disease have provided new targets for therapeu
217                          We report a case of Castleman's disease demonstrating 18F-fluorodeoxyglucose
218 primary effusion lymphoma, and some cases of Castleman disease.
219  systematic review of 404 published cases of Castleman's disease to identify the role of the surgeon
220                         As the complexity of Castleman disease is more fully understood, additional t
221 imary effusion lymphoma (PEL), and a form of Castleman disease (KSHV-MCD).
222 dy cavity-based lymphomas, and some forms of Castleman's disease.
223 ty-based lymphomas (BCBL), and some forms of Castleman's disease.
224   This review focuses on the intersection of Castleman disease and autoimmunity with an emphasis on s
225 inical types (localized and multicentric) of Castleman disease have been described.
226 enesis, both involved in the pathogenesis of Castleman disease, may provide additional unique therape
227 imary effusion lymphoma, and a proportion of Castleman's disease.
228 y effusion lymphomas (PELs), and a subset of Castleman's disease (CD).
229      Rational approaches to the treatment of Castleman disease have begun to have an impact on diseas
230 ling the multicentric plasma cell variant of Castleman's disease, characterized by persistent angiofo
231 there is mild FDG localization within pelvic Castleman's disease with standard uptake values lower th
232 ma-herpesvirus that causes Kaposi's sarcoma, Castleman's disease and primary effusion lymphomas in tr
233 d with histologically confirmed, symptomatic Castleman disease.
234  recent progress has been coordinated by the Castleman Disease Collaborative Network (CDCN), and furt
235 n 30 pathologically proved cases of thoracic Castleman disease were reviewed.
236 cal location of the only focus in unicentric Castleman's disease (UCD) or the dominant focus in multi
237 hieving long-term remission in patients with Castleman disease and associated autoimmune features.
238                            All patients with Castleman disease who were seen at Texas Medical Center,

 
Page Top